- Voyageur (VM) has signed a memorandum of understanding (MOU) with Rain Cage Carbon to develop radiographic drugs
- The companies intend to patent drugs, including iodine, gadolinium and iron oxide-based fullerene contrast agents for magnetic resonance imaging and nuclear imaging
- Fullerene-based contrast media drugs may lead to earlier detection of disease and provide a safer way to introduce toxic metals into the body
- CEO Brent Willis sat down with Daniella Atkinson to discuss fullerenes, their role in radiographic drugs, and the company’s development plans moving forward
- Voyageur is focused on the development of barium, iodine, and carbon APIs, as well as imaging contrast agents for the medical radiology marketplace
- Voyageur Pharmaceuticals (VM) opened unchanged, trading at $0.09 per share
Voyageur (VM) has signed an MOU with Rain Cage Carbon to develop radiographic drugs.
Rain Cage, a carbon capture company in Calgary, Alberta, offers technology that removes CO2 and other pollutants from hydrocarbon exhaust streams. The CO2 is converted into oxygen and carbon, creating fullerene allotropes and nanotubes that can enhance the strength, durability and ease of delivery for a variety of materials.
A fullerene is a carbon allotrope with atoms that can potentially act as a delivery system for a wide range of biomedical applications, including radiology contrast media, drug and gene delivery systems, anti-viral and anti-bacterial medications, photosensitizers, and antioxidants.
The new mineral-based radiographic drugs that Voyageur and Rain Cage intend to patent include iodine, gadolinium and iron oxide-based fullerene contrast agents for magnetic resonance imaging and nuclear imaging.
Fullerene-based contrast media drugs may lead to earlier detection of disease and provide a safer way to introduce toxic metals in the body than current methods in the market.
Net-zero pharmaceutical plant
Voyageur will deploy a Rain Cage carbon capture unit in its new pharmaceutical manufacturing plant, which is scheduled for construction in 2023, as part of its goal of becoming a low-carbon emitter in line with the U.N.’s 2030 sustainability goals.
The unit will produce carbon for R&D and potential new drug production.
CEO Brent Willis sat down with Daniella Atkinson to discuss fullerenes, their role in radiographic drugs, and the company’s development plans moving forward.
Voyageur is focused on the development of barium, iodine, and carbon APIs, as well as imaging contrast agents for the medical radiology marketplace.
Voyageur Pharmaceuticals (VM) opened unchanged, trading at $0.09 per share.
